Gotham Asset Management LLC Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Gotham Asset Management LLC grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 17.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 61,179 shares of the biotechnology company's stock after purchasing an additional 9,121 shares during the quarter. Gotham Asset Management LLC owned approximately 0.14% of United Therapeutics worth $21,586,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC raised its position in United Therapeutics by 0.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after purchasing an additional 39 shares during the period. Wedmont Private Capital acquired a new stake in shares of United Therapeutics during the fourth quarter valued at about $466,000. Signet Financial Management LLC raised its stake in shares of United Therapeutics by 1.0% in the 4th quarter. Signet Financial Management LLC now owns 10,816 shares of the biotechnology company's stock valued at $3,816,000 after acquiring an additional 103 shares during the period. Park Avenue Securities LLC lifted its holdings in shares of United Therapeutics by 18.4% in the 4th quarter. Park Avenue Securities LLC now owns 2,614 shares of the biotechnology company's stock worth $922,000 after acquiring an additional 407 shares during the last quarter. Finally, Burney Co. boosted its position in shares of United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after purchasing an additional 12,705 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at $11,261,606.58. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $956,195.85. This trade represents a 79.51% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 65,500 shares of company stock valued at $20,765,280. 11.90% of the stock is owned by insiders.

United Therapeutics Stock Down 1.8%

UTHR traded down $5.55 during trading on Tuesday, hitting $305.26. The company had a trading volume of 38,014 shares, compared to its average volume of 438,604. The firm's 50-day moving average price is $300.53 and its 200 day moving average price is $341.75. The company has a market capitalization of $13.77 billion, a PE ratio of 13.46, a PEG ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a one year low of $263.56 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the previous year, the firm posted $6.17 EPS. Sell-side analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Morgan Stanley increased their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a report on Thursday, May 1st. Finally, JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.